MedPath

5 days a week versus 6 days a week fractionated Radiotherapy in Cervical Carcinoma

Phase 3
Conditions
Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Registration Number
CTRI/2023/06/054226
Lead Sponsor
Prof Dr Sunil Choudhary
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

18- to 65- year-old females with histologically proven carcinoma cervix stage IB3 to IVA

Exclusion Criteria

Patients previously treated for any pelvic malignancy, lactating and pregnant females

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ocal control, Disease Free survival & Overall survivalTimepoint: 5 years
Secondary Outcome Measures
NameTimeMethod
ilTimepoint: Nil
© Copyright 2025. All Rights Reserved by MedPath